First AD

Second AD

A medical oncologist discusses the value of PD-L1 as a biomarker in the treatment of patients with nasopharyngeal carcinoma.

Value of PD-L1 Biomarker in NPC

Video content above is prompted by the following:

What is the value of PD-L1 as a biomarker in the treatment of patients with nasopharyngeal carcinoma?

Head & Neck Cancers

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer. 

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Clinical Advances in Nasopharyngeal Carcinoma

Yale Cancer Center

Cancer Centers

Partner

City of Hope

Differentiating Nasopharyngeal Carcinoma from Other Head & Neck Cancers: The Value of a Multidisciplinary Approach

Current Guidelines for Managing Nasopharyngeal Carcinoma

Overview of the JUPITER and POLARIS-2 Trials

Phase 3 DIPPER Trial: Adjuvant PD-1 Blockade with Camrelizumab

Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors

Strategies to Mitigate Adverse Events in Nasopharyngeal Carcinoma Treatment

Future Research Needs for Neoadjuvant/Adjuvant PD-1 Blockade in Nasopharyngeal Carcinoma

Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects

Clinical Scenario: Locally Recurrent NPC

Clinical Scenario: Metastatic EBV-Positive NPC